Article Text

Download PDFPDF
Patterns of Recurrence in Stage I Endometrioid Endometrial Adenocarcinoma With Lymphovascular Space Invasion
  1. Fiona Simpkins, MD*,,
  2. Andrea Papadia, MD, PhD,
  3. Charles Kunos, MD, PhD,
  4. Chad Michener, MD*,
  5. Heidi Frasure, MS§,
  6. Fadi AbuShahin, MD*,
  7. Andrea Mariani, MD,
  8. Jamie N. Bakkum-Gamez, MD,
  9. Lisa Landrum, MD,
  10. Kathleen Moore, MD,
  11. Sajeena G. Thomas, MD#,
  12. Alexandra Windhorn, MD# and
  13. Peter G. Rose, MD*
  1. *Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Cleveland, OH;
  2. Division of Gynecology Oncology, Department of Obstetrics and Gynecology, University of Miami, Miami, FL; Departments of
  3. Radiation Oncology and
  4. §OB-GYN, Biostatistics, University Hospitals of Cleveland, Cleveland, OH;
  5. Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN;
  6. Division of Gynecology Oncology, University of Oklahoma HSC, Oklahoma City, OK; and
  7. #Division of Gynecology Oncology, University of Minnesota, MN.
  1. Address correspondence and reprint requests to Fiona Simpkins, MD, Sylvester Comprehensive Cancer Center, Division of Gynecology Oncology, 1475 NW 12th Ave, Suite 3500, Miami, FL 33136. E-mail: fsimpkins{at}med.miami.edu; or Peter G. Rose, MD, Cleveland Clinic Foundation, Division of Gynecology Oncology, 9500 Euclid Ave, Desk A-81, Cleveland, OH 44195. E-mail: rosep{at}ccf.org.

Abstract

Objective The objective of this study was to determine the patterns of recurrence of stage IB–IIA endometrioid endometrial adenocarcinoma (EMCA) with lymphovascular invasion (LVSI).

Methods A multicenter retrospective study of 1988 International Federation of Gynecology and Obstetrics stage IB–IIA EMCA patients with LVSI treated with surgery with or without radiation was conducted. Those with papillary serous or clear cell histologies and women treated with chemotherapy were excluded. Data regarding surgical-pathologic factors, treatment, and outcome were collected. Data were analyzed using χ2 test, Kaplan-Meier estimates, and Cox multivariate proportional hazards models.

Results From 1997 to 2008, we identified 131 patients with LVSI who met entry criteria among 5 institutions. Median age was 67 years (25%–75%: 60–75 years), and median follow-up was 4.25 years (25%–75%: 3–10 years). Following surgery, 45 patients were observed (Obs), and 86 patients received adjuvant radiation. We observed 30 total relapses 30/131 (23%): 11/45 (24%) in the Obs group and 19/86 (22%) in the adjuvant radiation group. Recurrence rates were similar between staged and unstaged patients: 24% (20/84) and 21% (10/47), respectively. Among Obs patients, 82% of relapses were local, whereas in patients treated with adjuvant radiation, 84% were distant. Relapses were significantly associated with invasion of the lower uterine segment (LUS) (P = 0.035). Both cancer-related survival and overall survival (OS) were not significantly impacted by adjuvant radiation, because of distant failure rates. Adjuvant radiation significantly improved pelvic control (P = 0.007). In a multivariate analysis, OS correlated with LUS invasion (P = 0.008) and was borderline-associated with stage (P = 0.06), whereas age (P = 0.12), grade (P = 0.31), myometrial invasion (P = 0.99), and radiation treatment (P = 0.23) were not.

Conclusions Overall recurrence rates for stage IB–IIA EMCA patients with LVSI are high (23%). Although adjuvant radiation therapy improved pelvic control, it did not impact recurrence rates, cancer-related survival, and OS, likely secondary to distant failures. The role of systemic therapy with or without radiotherapy for early-stage EMCA with LVSI should be evaluated, particularly in patients with high-grade tumors or involvement of the LUS.

  • Lymphovascular invasion
  • Endometrial cancer
  • Patterns of recurrence

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.